Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to DeclineZacks Investment Research • 01/26/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 01/26/23
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6Business Wire • 01/26/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 01/26/23
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 01/25/23
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?Zacks Investment Research • 01/24/23
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 01/24/23
SHAREHOLDER ALERT: Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Announces Investigation of Surmodics, Inc. (SRDX)Newsfile Corp • 01/23/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) InvestigationBusiness Wire • 01/20/23
SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDXBusiness Wire • 01/19/23
Differentiated Capabilities of Surmodics' Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET ConferenceBusiness Wire • 01/19/23
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated BalloonBusiness Wire • 01/19/23
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18Business Wire • 01/16/23
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposiumBusiness Wire • 11/17/22
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16Business Wire • 11/11/22
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial GuidanceBusiness Wire • 11/09/22
24-Month Data from Surmodics' TRANSCEND Trial Presented at VIVA 2022 ConferenceBusiness Wire • 11/02/22
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9thBusiness Wire • 10/28/22
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022Business Wire • 10/26/22
Surmodics Announces New Credit Facilities Providing up to $125 Million in FinancingBusiness Wire • 10/17/22
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP EuropeBusiness Wire • 10/11/22